Ben Scruggs | Human Intestinal Tissue Models and Predictive Drug Development
Ben Scruggs joins Executive Insights for Life Sciences Innovators to discuss advanced tissue platforms, predictive drug development, biotechnology infrastructure, and improving translational accuracy in preclinical research.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Ben Scruggs discusses how Altis Biosystems is developing advanced human intestinal tissue platforms designed to improve drug development predictability. The conversation explores the limitations of traditional gut models, the role of the RepliGut® platform in translational research, and the operational and financial realities of building scalable platform biotechnology companies.
Key Themes
- Advanced human intestinal tissue platforms
- Improving predictability in drug development
- Translational limitations of traditional gut models
- The RepliGut® platform and preclinical innovation
- Scaling platform biotechnology companies
- Capital discipline and durable life sciences infrastructure
Why This Matters for Life Sciences Leaders
As biotechnology and pharmaceutical companies seek to reduce clinical trial risk and improve translational outcomes, more predictive preclinical models are becoming increasingly important. The conversation highlights how advanced tissue platforms may help improve drug development efficiency while also underscoring the leadership, operational discipline, and long-term strategy required to build durable life sciences infrastructure companies.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
